Concannon Thomas W, Kent David M, Normand Sharon-Lise, Newhouse Joseph P, Griffith John L, Cohen Joshua, Beshansky Joni R, Wong John B, Aversano Thomas, Selker Harry P
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA.
Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):506-13. doi: 10.1161/CIRCOUTCOMES.109.908541. Epub 2010 Jul 27.
Primary percutaneous coronary intervention (PCI) is more effective on average than fibrinolytic therapy in the treatment of ST-segment-elevation myocardial infarction. Yet, most US hospitals are not equipped for PCI, and fibrinolytic therapy is still widely used. This study evaluated the comparative effectiveness of ST-segment-elevation myocardial infarction regionalization strategies to increase the use of PCI against standard emergency transport and care.
We estimated incremental treatment costs and quality-adjusted life expectancies of 2000 patients with ST-segment-elevation myocardial infarction who received PCI or fibrinolytic therapy in simulations of emergency care in a regional hospital system. To increase access to PCI across the system, we compared a base case strategy with 12 hospital-based strategies of building new PCI laboratories or extending the hours of existing laboratories and 1 emergency medical services-based strategy of transporting all patients with ST-segment-elevation myocardial infarction to existing PCI-capable hospitals. The base case resulted in 609 (95% CI, 569-647) patients getting PCI. Hospital-based strategies increased the number of patients receiving PCI, the costs of care, and quality-adjusted life years saved and were cost-effective under a variety of conditions. An emergency medical services-based strategy of transporting every patient to an existing PCI facility was less costly and more effective than all hospital expansion options.
Our results suggest that new construction and staffing of PCI laboratories may not be warranted if an emergency medical services strategy is both available and feasible.
在治疗ST段抬高型心肌梗死方面,直接经皮冠状动脉介入治疗(PCI)平均比纤维蛋白溶解疗法更有效。然而,美国大多数医院未配备PCI设备,纤维蛋白溶解疗法仍被广泛使用。本研究评估了ST段抬高型心肌梗死区域化策略相对于标准紧急转运和治疗在增加PCI使用方面的比较效果。
在一个区域医院系统的急诊护理模拟中,我们估计了2000例接受PCI或纤维蛋白溶解疗法的ST段抬高型心肌梗死患者的增量治疗成本和质量调整预期寿命。为了增加整个系统对PCI的可及性,我们将一个基础病例策略与12种基于医院的策略(新建PCI实验室或延长现有实验室的工作时间)以及1种基于紧急医疗服务的策略(将所有ST段抬高型心肌梗死患者转运至现有具备PCI能力的医院)进行了比较。基础病例策略导致609例(95%CI,569 - 647)患者接受PCI。基于医院的策略增加了接受PCI的患者数量、护理成本以及节省的质量调整生命年,并且在各种情况下都具有成本效益。一种基于紧急医疗服务的将每位患者转运至现有PCI设施的策略比所有医院扩张方案成本更低且更有效。
我们的结果表明,如果紧急医疗服务策略既可行又可用,那么新建PCI实验室并配备人员可能并无必要。